Functional and morphological changes of the retinal vessels in Alzheimer’s disease and mild cognitive impairment

Giuseppe Querques1, Enrico Borrelli2, Riccardo Sacconi1, Luigi De Vitis1, Letizia Leocani3, Roberto Santangelo1, Giuseppe Magnani3, Giancarlo Comi3 & Francesco Bandello1

Imaging and histopathological studies have demonstrated that structural changes of the retina affect subjects with Alzheimer’s disease (AD) or mild cognitive impairment (MCI). The aim of this study was to quantitatively investigate the retinal vessels in these disorders, using dynamic vessel analyzer (DVA) and optical coherence tomography angiography (OCTA) analysis. Twelve subjects with AD, 12 subjects with MCI, and 32 gender- and age-matched controls were prospectively enrolled. Mean ± SD age was 72.9 ± 7.2 years in the AD group, 76.3 ± 6.9 years in the MCI group, and 71.6 ± 5.9 years in the control group (p = 0.104). In the DVA dynamic analysis, the arterial dilation was decreased in the AD group (0.77 ± 2.06%), in the comparison with the control group (3.53 ± 1.25%, p = 0.002). The reaction amplitude was decreased both in AD (0.21 ± 1.80%, < 0.0001) and MCI (2.29 ± 1.81%, p = 0.048) subjects, compared with controls (3.86 ± 1.94%). OCTA variables did not differ among groups. In the Pearson correlation analysis, amyloid β level in the cerebrospinal fluid was directly correlated with the arterial dilation (R = 0.441, p = 0.040) and reaction amplitude (R = 0.580, p = 0.005). This study demonstrate that Alzheimer’s and MCI subjects are characterized by a significant impairment of the retinal neurovascular coupling. This impairment is inversely correlated with the level of amyloid β in the cerebrospinal fluid.

Alzheimer’s disease (AD) is the most common form of neurodegeneration among older individuals in developed countries, with an estimated prevalence of 36.5 million1. This form of dementia is clinically characterized by severe cognitive decline and socio-behavioral manifestations1. Furthermore, subjects with AD may experience visual impairment, including narrowed visual field, dyschromatopsia, deficits in contrast sensitivity, abnormal eye movements, and alteration in visual-evoked potentials2.

Alzheimer’s disease is preceded by a variable transitional phase, which affects older subjects with heterogeneous cognitive and functional impairment, the latter not crossing the threshold for dementia. This condition has been termed “mild cognitive impairment” (MCI) and the affected patients have an increased risk of developing dementia, especially AD3,4.

AD is a complex disease with multifactorial etiologies. Many factors have been implicated in the pathogenesis and progression of this disorder, the earliest and most important is known to be a continuum of detrimental processes, most likely beginning with the accumulation of misfolded amyloid β-protein (Aβ) and hyperphosphorylation of tau proteins, which shape neurofibrillary tangles5. This accumulation of debris is thought to initiate a cascade of secondary processes, which involve inflammation, oxidative stress, vascular abnormalities, and neuronal loss6,7. Of note, small vessel disease of the brain has been demonstrated to be implicated in AD and MCI pathogenesis8. Furthermore, these neurodegenerative disorders are associated with early neurovascular dysfunction, which leads to an altered blood flow regulation and contributes to disease pathogenesis9,10.

1 Ophthalmology Department, San Raffaele University Hospital, Milan, Italy. 2 Ophthalmology Clinic, Department of Medicine and Science of Ageing, University G. D’Annunzio Chieti-Pescara, Chieti, Italy. 3 Department of Neurology and Institute of Experimental Neurology-INSPE, San Raffaele University Hospital, Milan, Italy. Correspondence and requests for materials should be addressed to G.Q. (email: giuseppe.querques@hotmail.it).
Although cerebral small vessel disease has thus been implicated in the development of AD and MCI, the cerebral microcirculation remains difficult to investigate in vivo. Since the cerebral and retinal vasculature have similarities regarding embryological origin, anatomical features and physiological properties, investigating the retinal vessels may thus be valuable in providing new insights into the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Furthermore, the morphological and functional characteristics of the retinal vessels might be useful as indicators of disease progression.

Of note, some reports have already shown that retinal vascular alterations may be present in eyes of subjects with AD or MCI. Nevertheless, all these descriptions have been made using fundus photographs. The introduction of new imaging modalities has however revolutionized retinal imaging. These techniques allow topographic qualitative investigation and quantitative measurements of vessels at various depth-resolved levels of the retina.

Recent studies have investigated the retinal microvascular networks in normal and pathologic states using dynamic vessel analyzer (DVA) and optical coherence tomography angiography (OCTA) devices in adults and children.

However, to the best of our knowledge, detailed description of the functional and morphological characteristics of the macular microvasculature in AD and MCI subjects has not been performed. The aim of this study was thus to explore retinal vessels in subjects affected by AD or MCI, using DVA and OCTA analysis.

Methods

Study participants. This study is a prospective, observational, case-control study. Subjects with a clinical confirmed diagnosis of Alzheimer’s disease or mild cognitive impairment were enrolled from the ophthalmology and neurology departments at the San Raffaele Hospital in Milan, Italy. The study was approved by the San Raffaele Institutional Review Board and adhered to the tenets of the Declaration of Helsinki and Health Insurance Portability and Accountability Act. Written informed consent was obtained from all subjects prior to enrollment in the study.

Before the enrollment, all affected subjects underwent a standardized dementia assessment, which included: (i) Mini-Mental State Examination (MMSE), (ii) medical history collection, (iii) physical and neurological examination, (iv) neuropsychological testing, (v) electrocardiogram, (vi) electroencephalography, (vii) blood tests (VDRL serologic screening tests for syphilis, thyroid function, vitamin B12, folate and homocysteine), and (viii) either standard (computed tomography and/or magnetic resonance imaging) or functional neuroimaging with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG PET), in order to rule out other potential causes accounting for cognitive decline. Moreover, quantification of cerebrospinal fluid (CSF) biomarkers (Aβ, tau protein, and phosphorylated tau protein) was performed in all subjects. Of note, the CSF biomarkers were considered positive in agreement to the international normative criteria: Aβ42 was higher than 500 ng/L, t-tau protein was lower than 350 ng/L, and phosphorylated tau protein was lower than 61 ng/L. Finally, the diagnosis of AD and MCI was made following the NIA-AA criteria. Exclusion criteria were the presence of any other neurologic or psychiatric disorders, including suspicion of other types of dementia. Assuming age may affect retinal and vascular parameters, a control group matched for age was also included in the current analysis. Control subjects were volunteers with no evidence of cognitive impairment (based on the MMSE assessment) or neurological/psychiatric disorder.

Exclusion criteria for either patient and control group were: (i) history of diabetes mellitus, uncontrolled hypertension, heart disease, or other serious chronic medical conditions; (ii) significant media opacity; (iii) evidence of optic nerve or retinal disease, as evaluated by dilated fundus examination and OCT/OCTA; (iv) refractive error greater than 6 diopters; and (v) pharmacologic pupillary dilation lower than 6 mm.

All AD/MCI subjects and controls were enrolled between May 2016 and May 2017 and received a complete ophthalmologic examination, which included the measurement of best-corrected visual acuity (BCVA), intraocular pressure, and dilated ophthalmoscopy. BCVA measurements were made using a Snellen chart and were converted to the logarithm of the minimum angle of resolution (LogMAR). Finally, either pathological and healthy control group underwent DVA, OCTA, and OCT imaging.

Dynamic vessel analyzer. The DVA (DVA; Imedos Systems UG, Jena, Germany) is a commercially available system which is composed of a fundus camera, video camera, real-time monitor, and a personal computer with analysis software.

The DVA examination has been described in depth in previous reports. In brief, this device tests the retinal vessel changes in response to diffuse luminance flicker (dynamic analysis). During the examination, the subject focuses into the retinal camera in order to allow the examiner to visualize the subject’s fundus with a red-free light. An arteriolar and venular segments are thus selected and their changes in diameter are recorded and measured at baseline and during/after a flickering-light stimulation. Of note, this stimulation lasts 20 seconds and then the previously selected vessels are measured for 80 seconds. This cycle of stimulation and measurements was repeated twice in each eye, with a total duration of the examination of 350 seconds per eye. Importantly, the system works by automatically suspending the test when subjects blink or move their eyes.

Therefore, retinal arteriolar and venular changes in diameter in response to flickering light are calculated automatically by the DVA software (after averaging the two obtained examinations for each eye) and reported as percentage (%) in comparison with baseline diameter. During DVA testing, healthy eyes are characterized by a characteristic response curve to flicker light: primary vasodilation and secondary vasoconstriction. The main outcome measures of this dynamic analysis were: (i) arterial dilation; (ii) arterial constriction; (iii) reaction amplitude (the difference between arterial dilation and constriction); and (iv) venous dilation (Fig. 1).

In addition, the DVA software provided other secondary outcomes, which are dependent on the baseline assessment of the retinal vessels (static analysis). These parameters are calculated by measuring the average diameter of all those arterioles and venules within an annulus around the optic disc. The obtained parameters...

Assuming age may affect retinal and vascular parameters, a control group matched for age was also included in the current analysis. Control subjects were volunteers with no evidence of cognitive impairment (based on the MMSE assessment) or neurological/psychiatric disorder.

Exclusion criteria for either patient and control group were: (i) history of diabetes mellitus, uncontrolled hypertension, heart disease, or other serious chronic medical conditions; (ii) significant media opacity; (iii) evidence of optic nerve or retinal disease, as evaluated by dilated fundus examination and OCT/OCTA; (iv) refractive error greater than 6 diopters; and (v) pharmacologic pupillary dilation lower than 6 mm.

All AD/MCI subjects and controls were enrolled between May 2016 and May 2017 and received a complete ophthalmologic examination, which included the measurement of best-corrected visual acuity (BCVA), intraocular pressure, and dilated ophthalmoscopy. BCVA measurements were made using a Snellen chart and were converted to the logarithm of the minimum angle of resolution (LogMAR). Finally, either pathological and healthy control group underwent DVA, OCTA, and OCT imaging.

Dynamic vessel analyzer. The DVA (DVA; Imedos Systems UG, Jena, Germany) is a commercially available system which is composed of a fundus camera, video camera, real-time monitor, and a personal computer with analysis software.

The DVA examination has been described in depth in previous reports. In brief, this device tests the retinal vessel changes in response to diffuse luminance flicker (dynamic analysis). During the examination, the subject focuses into the retinal camera in order to allow the examiner to visualize the subject’s fundus with a red-free light. An arteriolar and venular segments are thus selected and their changes in diameter are recorded and measured at baseline and during/after a flickering-light stimulation. Of note, this stimulation lasts 20 seconds and then the previously selected vessels are measured for 80 seconds. This cycle of stimulation and measurements was repeated twice in each eye, with a total duration of the examination of 350 seconds per eye. Importantly, the system works by automatically suspending the test when subjects blink or move their eyes.

Therefore, retinal arteriolar and venular changes in diameter in response to flickering light are calculated automatically by the DVA software (after averaging the two obtained examinations for each eye) and reported as percentage (%) in comparison with baseline diameter. During DVA testing, healthy eyes are characterized by a characteristic response curve to flicker light: primary vasodilation and secondary vasoconstriction. The main outcome measures of this dynamic analysis were: (i) arterial dilation; (ii) arterial constriction; (iii) reaction amplitude (the difference between arterial dilation and constriction); and (iv) venous dilation (Fig. 1).

In addition, the DVA software provided other secondary outcomes, which are dependent on the baseline assessment of the retinal vessels (static analysis). These parameters are calculated by measuring the average diameter of all those arterioles and venules within an annulus around the optic disc. The obtained parameters...
are, as follows: (i) central retinal artery equivalent (CRAE); (ii) central retinal vein equivalent (CRVE); and (iii) artery-vein ratio (AVR – obtained by dividing CRVE by CRAE).

**Optical Coherence Tomography Angiography.** All enrolled subjects underwent two OCTA successive scans using OCTA software (Cirrus 5000 with Angioplex™; Carl Zeiss Meditech) and covering $3 \times 3$-mm and $6 \times 6$-mm area centered on the fovea, respectively.

The main OCTA outcome measures were: (i) superficial vascular plexus (SVP) perfusion density; (ii) deep vascular plexus (DVP) perfusion density; (iii) choriocapillaris (CC) perfusion density; and (iv) choroidal perfusion density.

An experienced grader (RS), masked for subject information, checked the quality of all images and only eyes with OCTA images of sufficient quality were included in the image processing. For each eye, we exported the SVP, DVP, CC and choroid en face OCTA scans, which were automatically segmented by the Angioplex™ software, as previously described\(^2^6,2^7\). The three en face images were then imported into image analysis ImageJ software version 1.50 (National Institutes of Health, Bethesda, MD; available at [http://rsb.info.nih.gov/ij/index.html]\(^2^8\)).

To calculate the perfusion density, a previously described thresholding algorithm was applied to the en face images to create binary images\(^2^9,3^0\). In brief, the images were first converted from RGB to 8-bit. Then, the images were binarized using the “mean” thresholding method. The perfusion density was thus calculated as a proportion of the number of pixels over the threshold divided by the total number of pixels in the analyzed area. Of note, in the SVP and DVP measurements, the region corresponding to the foveal avascular zone (FAZ) was masked.

**Optical Coherence Tomography.** The SPECTRALIS HRA + OCT device (Heidelberg Engineering, Heidelberg, Germany) was used for the spectral domain OCT examination. The protocol of acquisition consisted in 19 B-scan sections centered on the fovea. This acquisition allowed the software to automatically segment the retinal layers and produce a thickness map for each of them\(^3^1\).

The algorithm identified and calculated the difference between the inner limiting membrane (ILM) and the retinal pigment epithelium (RPE), and yielded the average macular thickness. Moreover, the algorithm provided the average thickness of the following slabs: (i) retinal nerve fiber layer (RNFL); (ii) ganglion cell layer (GCL); (iii) inner plexiform layer (IPL); and (iv) ganglion cell complex (GCC - resulted as GCL + IPL). The software provided the average sectorial thicknesses (superior, inferior, nasal, temporal) in two different rings centered on the fovea (dimensions: inner and outer diameters of 3 and 6 mm, respectively). In addition, the central thickness is referred to the average thickness in the 1-mm diameter central circle.

**Statistical analysis.** Statistical calculations were performed using Statistical Package for Social Sciences (version 20.0, SPSS Inc., Chicago, IL, USA).

To detect departures from normal distribution, a Shapiro-Wilk’s test was performed for all variables. Means and standard deviation (SD) were computed for all quantitative variables. Continuous variables were compared by conducting a Student T-test for independent variables or a one-way analysis of variance (ANOVA) with Bonferroni post-hoc test. Statistical significance of the differences between groups for qualitative variables was...
assessed using Fisher’s exact test. Pearson’s chi-squared correlation was performed to evaluate the linear correlation between the CSF level of Aβ, tau and phosphorylated-tau proteins and functional/anatomic metrics. The latter test was performed by considering together AD and MCI subjects. A p value of 0.05 was considered for statistical significance.

**Results**

**Characteristics of subjects included in the analysis.** Twelve subjects with AD (8 females), 12 subjects with MCI (7 females), and 32 gender- and age-matched controls (15 females) were included in the analysis (ANOVA for difference in gender: p = 0.469). One eye for each subject was randomly selected and included in the analysis.

Mean age was 72.9 ± 7.2 years [range 58–81 years] in the AD group, 76.3 ± 6.9 years [range 59–87 years] in the MCI group, and 71.6 ± 5.9 years [range 45–84 years] in the control group (p = 0.104). The BCV A was 0.2 ± 0.2 LogMAR (Snellen VA of 20/32) in the AD group, 0.1 ± 0.1 LogMAR (Snellen VA of 20/25) in the MCI group, and 0.1 ± 0.1 LogMAR (Snellen VA of 20/25) in the healthy eyes (p = 0.090).

Neurological characteristics of AD and MCI subjects are described in Table 1.

| Characteristic                  | AD (n=12) | MCI (n=12) |
|---------------------------------|-----------|------------|
| MMSE, mean ± SD               | 24.9/30 ± 2.7/30 | 20.7/30 ± 3.6/30 |
| Corrected MMSE, mean ± SD     | 23.7/30 ± 2.4/30 | 19.5/30 ± 3.6/30 |
| CSF - Amyloid β (ng/L), mean ± SD | 514.55 ± 182.75 | 486.90 ± 100.91 |
| Negative (%)                   | 50.0      | 66.7       |
| Positive (%)                   | 50.0      | 33.3       |
| CSF - Tau protein (ng/L), mean ± SD | 515.27 ± 364.14 | 527.30 ± 298.35 |
| Negative (%)                   | 75.0      | 44.4       |
| Positive (%)                   | 25.0      | 55.6       |
| CSF - Phosphorylated tau (ng/L), mean ± SD | 81.91 ± 41.90 | 83.90 ± 49.91 |
| Negative (%)                   | 75.0      | 22.2       |
| Positive (%)                   | 25.0      | 77.8       |
| Arterial hypertension          |           |            |
| Absent (%)                     | 54.5      | 36.4       |
| Under treatment (%)            | 36.4      | 63.6       |
| Bad controlled (%)             | 9.1       | 0          |
| Cerebrovascular disease        |           |            |
| Negative (%)                   | 36.4      | 54.5       |
| Positive (%)                   | 63.6      | 45.5       |

Table 1. Neurological parameters in affected subjects. *T*-student test p value is < 0.05; †Fisher’s exact test p value is < 0.05. MCI: mild cognitive impairment; AD: Alzheimer’s disease; MMSE: mini-mental state examination; SD: standard deviation; CSF: cerebrospinal fluid; 18FDG PET: 18fluorodeoxyglucose positron emission tomography.

**Functional metrics – Dynamic Vessel Analyzer.** Using DVA, we investigated both vascular static and dynamic changes in AD and MCI subjects. In the static analysis, none of the analyzed parameters (AVR, CRAE, and CRVE) differed among groups (Table 2). In the dynamic analysis, the arterial dilation was decreased in the AD group (0.77 ± 2.06%), in the comparison with both the MCI (2.84 ± 2.18%, p = 0.045) and control (3.53 ± 1.25%, p = 0.002) groups. Neither arterial constriction nor venous dilation differed among groups. The reaction amplitude was decreased both in AD (0.21 ± 1.80%, < 0.0001) and MCI (2.29 ± 1.81%, p = 0.048) subjects, compared to controls (3.86 ± 1.94%) (Table 2, Fig. 2).

**Anatomic metrics.** Optical coherence tomography was carried out to assess GCL thickness in enrolled subjects, since neuroretinal changes have been demonstrated to occur in AD and MCI subjects. Notably, the average GCL thickness was reduced in AD subjects compared to controls, but only in the central (12.59 ± 2.60µm versus 15.02 ± 2.74µm, p = 0.025) and temporal (42.05 ± 4.95 µm versus 47.02 ± 5.27µm, p = 0.040) sectors (Table 3, Fig. 3).

No differences in OCTA parameters were found among groups in either 3 × 3 and 6 × 6 scan (Table 4, Fig. 4). This was in disagreement with the Bulut and colleagues’ paper (see Discussion section).

**Correlation analysis.** In the Pearson correlation analysis, the CSF amyloid β level was directly correlated with the arterial dilation (R = 0.441, p = 0.040) and reaction amplitude (R = 0.580, p = 0.005). Furthermore, the CSF amyloid β amount was directly correlated with the central GCL average thickness (R = 0.530, p = 0.011) and the central IPL average thickness (R = 0.497, p = 0.019). The central IPL average thickness was inversely correlated with the CSF phosphorylated-tau quantity. Other significant correlations are reported in Table 5.
Discussion

In this cross-sectional study we investigated quantitative data of retinal vessels in eyes of subjects with Alzheimer’s disease or mild cognitive impairment. Overall we found that subjects with AD are characterized by a significant impairment of the retinal neurovascular coupling. Noteworthy, results of the present study demonstrated that similar alterations feature subjects with MCI.

| Dynamic Analysis                  | AD       | MCI       | Controls |
|----------------------------------|----------|-----------|----------|
| **Arterial dilation (%)**        | 0.77 ± 2.06 | 2.84 ± 2.18 | 3.53 ± 1.25 |
|                                  | 0.045    | 0.002     |          |
|                                  | —        | 1.0†      |          |
| **Arterial constriction (%)**    | 0.59 ± 0.88 | 0.55 ± 1.28 | — 0.33 ± 1.17 |
|                                  | 1.0†     | 0.163     | 0.199†   |
| **Reaction amplitude (%)**      | 0.21 ± 1.80 | 2.29 ± 1.81 | 3.86 ± 1.94 |
|                                  | 0.038    | <0.0001*  | 0.048*   |
|                                  | —        | 0.0001*   |          |
| **Venous dilation (%)**         | 2.84 ± 1.56 | 3.45 ± 1.96 | 3.37 ± 1.81 |
|                                  | 1.0†     | 0.833     | 1.0†     |

| Static Analysis                  |          |          |          |
|----------------------------------|----------|----------|----------|
| **AVR**                          | 0.92 ± 0.10 | 0.83 ± 0.10 | 0.89 ± 0.06 |
|                                  | 0.070†    | 1.0†     |          |
|                                  | —        | 0.236*   |          |
| **CRAE**                         | 189.81 ± 25.18 | 177.94 ± 26.92 | 186.77 ± 23.63 |
|                                  | 0.924†    | 1.0†     | 1.0†     |
|                                  | —        | 1.0†     |          |
| **CRVE**                         | 208.04 ± 28.31 | 213.78 ± 16.60 | 207.31 ± 16.53 |
|                                  | 1.0†     | 1.0†     | 1.0†     |

Table 2. Dynamic vessel analyzer parameters in affected subjects and controls. * †ANOV A test with Bonferroni post-hoc *Comparison versus AD; †Comparison versus MCI. Data are presented as mean ± SD (standard deviation). AD: Alzheimer’s disease; MCI: mild cognitive impairment; AVR: artery-vein ratio; CRAE: central retinal artery equivalent; CRVE: central retinal vein equivalent.

Figure 2. Representation of Alzheimer’s and healthy cases. Example of dynamic vessel analyzer curve in a healthy control (top image) and in an Alzheimer’s subject (bottom image). In the affected subject, a loss of dilation and constriction, as well as an overall decrease in amplitude, indicate significant dysfunction of the response to flicker stimulus.
Table 3. Optical coherence tomography parameters in affected subjects and controls. *ANOVA p value is < 0.05; †Statistically significant different compared to control. Data are presented as mean ± SD (standard deviation). AD: Alzheimer’s disease; MCI: mild cognitive impairment; RNFL: retinal nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; GCC: ganglion cell complex (GCC is equivalent to GCL + IPL).
Although AD is thought to be a disorder which mainly affects the brain, several evidences suggest that the retina may be affected\(^3\)\(^5\)-\(^4\)\(^2\). Several approaches have been used to demonstrate that the degeneration of the retinal ganglion cells is associated with AD, perhaps offering an effective measure of neurodegenerative progression\(^3\)\(^7\)-\(^3\)\(^9\). Histopathological studies analyzed the postmortem retinas from subjects with AD and demonstrated a reduction in the number of the retinal ganglion cells and their axons in the nerve fiber layer\(^3\)\(^7\)-\(^3\)\(^9\). This cell loss has been speculated to be secondary to the presence of extracellular plaques and intracellular A\(_\beta\) deposits in the retina of subjects with Alzheimer’s disease\(^4\)\(^0\). Different studies have used OCT to demonstrate that the GCL thickness is reduced in AD populations\(^3\)\(^2\)-\(^3\)\(^5\),\(^4\)\(^1\),\(^4\)\(^2\).

**Table 4.** Optical coherence tomography angiography parameters in affected subjects and controls. Data are presented as mean ± SD (standard deviation). AD: Alzheimer’s disease; MCI: mild cognitive impairment; SVP: superficial vascular plexus; DVP: deep vascular plexus; SD, standard deviation; *ANOVA p value < 0.05; *Statistically significant different if compared to control.

**Figure 3.** OCT scan from a healthy subject. The average macular thickness was measured as the difference between the inner limiting membrane (ILM) and the retinal pigment epithelium (RPE) (image A). Moreover, the algorithm provided the average thickness of the ganglion cell layer (GCL – image B), retinal nerve fiber layer (RNFL – image C), and inner plexiform layer (IPL – image D). (E) The build-in software provided the sectorial thicknesses (superior, inferior, nasal, temporal) in two different rings centered on the fovea (dimensions: inner and outer diameters of 3 and 6 mm, respectively). In addition, the central thickness was referred to the average thickness in the 1-mm diameter central circle.

**Figure 4.** OCTA images from a healthy subject. (a) The image of the superficial vascular plexus (SVP) was first imported in image analysis ImageJ software (National Institutes of Health; http://imagej.nih.gov/ij/)\(^2\)\(^8\). This image was then binarized with a “mean” method (b). The perfusion density was thus calculated as a unitless proportion of the number of pixels over the threshold (white area in the b and c images)) divided by the total number of pixels in the analyzed scan area. Of note, the region of the foveal avascular zone (blue in image c) was masked before measuring the perfusion density.
Therefore, taken these data together, we may speculate that an increased pathological 
amyloid amount is thus correlated with an impaired vascular function and that precede the retinal neuronal loss. Since MCI have an increased risk of developing AD, there is significant interest in the clinical characterization of these subjects and in finding new clinical parameters which may be used to predict clinical progression.

In our study, DVA analysis showed that even MCI subjects are characterized by an alteration of the vascular response to flicker stimulus. These results may suggest that these functional alterations are early in the pathogenesis and that precede the retinal neuronal loss. Since MCI have an increased risk of developing AD, there is significant interest in the clinical characterization of these subjects and in finding new clinical parameters which may help in the diagnosis and eventually predict the transition from MCI to AD. If replicated in future studies, DVA analysis may prove to be a useful parameter for characterizing subjects with cognitive impairment. Furthermore, a prospective longitudinal evaluation of retinal vessels in MCI subjects might clarify if retinal vascular assessment may be used to predict clinical progression.

Our results are in disagreement with those shown by Kotliar and colleagues, who demonstrated an increase arterial vasodilation in both AD and MCI groups. However, in the Kotliar et al’s study the enrolled subjects did not undergo an ophthalmological evaluation before enrollment and this might have affected their results, since neuronal alterations are known to be predominant in both AD and MCI. Additionally, our study cohort was investigated with OCTA, which provides a morphological characterization of the retinal and anterior choroidal vessels without the need for dye injection. Moreover, OCTA has the additional advantage of depth-resolution with better visualization of the deeper vascular layers, with consequent improved vascular characterization in several ocular and systemic diseases.

| Aβ3 | tau | phosphorylated tau |
|-----|-----|---------------------|
| r   | p-value | r   | p-value | r   | p-value |
| Arterial dilation | 0.441 | 0.040 | -0.429 | 0.046 | 0.470 | 0.027 | 0.519 | 0.013 | 0.424 | 0.049 |
| Reaction amplitude | 0.580 | 0.005 | -0.437 | 0.042 | 0.440 | 0.041 | 0.453 | 0.039 |

Table 5. Pearson correlations reaching statistical significance. Aβ3: amyloid β; CRAE: central retinal artery equivalent; CRVE: central retinal vein equivalent; GCL: ganglion cell layer; IPL: inner plexiform layer; GCC, ganglion cell complex (GCL + IPL).
disorders, including other neurodegenerative diseases\textsuperscript{53}. Bulut \textit{et al.} first investigated AD subjects using OCTA. In the latter study, the authors enrolled 26 AD subjects and 26 age-matched healthy controls and demonstrated that AD eyes are characterized by a reduced retinal vascular density. Of note, we demonstrated that AD subjects are characterized by a slightly reduction in flow in the deep vascular plexus, which however did not reach statistical significance. These results seem to suggest that functional alterations of the retinal vessels precede their morphological changes. Further studies with larger sample size are required to address this important point.

The main limitation of our study is the employment of a single time point for each patient. A prospective longitudinal evaluation of retinal vessels in AD and MCI subjects will shed further light on the role of the vascular damage on the structural alterations of the retina. Another limitation is the small sample size of affected subjects, which makes it difficult to draw conclusions to the overall AD or MCI population.

In conclusion, this is the first fully integrated report of the retinal vessels in subjects with either AD or MCI. We demonstrated that vascular changes characterize these disorders and that such alterations are mainly limited to the arterial function, rather than a vascular loss. Future studies with extended longitudinal follow up of the studied cohort may provide additional substantive information and retinal vascular parameters may prove to be a useful biomarker for monitoring the efficacy of AD and MCI, or to predict the disease progression.

References

1. Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. \textit{Lancet} \textbf{368}, 387–403 (2006).
2. Sadun, A. A., Borchert, M., DeVita, E., Hinton, D. R. & Bassi, C. J. Assessment of visual impairment in patients with Alzheimer's disease. \textit{Am. J. Ophthalmol.} \textbf{104}, 113–120 (1987).
3. Morris, J. C. \textit{et al.} Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. \textit{Arch. Neurol.} \textbf{58} (2001).
4. Petersen, R. C. \textit{et al.} Mild cognitive impairment: clinical characterization and outcome. \textit{Arch. Neurol.} \textbf{56}, 303–8 (1999).
5. Bateman, R. J. \textit{et al.} Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. \textit{N. Engl. J. Med.} \textbf{367}, 795–804 (2012).
6. Snyder, H. M. \textit{et al.} Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. \textit{Alzheimer's and Dementia} \textbf{11}, 710–717 (2015).
7. Serrano-Pozo, A. \textit{et al.} Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in alzheimer disease. \textit{J. Neuropathol. Exp. Neurol.} \textbf{72}, 462–471 (2013).
8. Frontczak-Baniewicz, M., Andrychowsky, J., Czernecki, Z. & Walski, M. Involvement of immature endothelial cells in vascular alterations in Alzheimer's disease. \textit{Folia Neuropathol} \textbf{44}, 17–23 (2006).
9. Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer’s disease. \textit{J. Cereb. Blood Flow Metab.} \textbf{35}, 1055–1068 (2015).
10. Arvanitakis, Z., Capeauo, A. W., Leurgans, S. E., Bennett, D. A. & Schneider, J. A. Relation of cerebral vessel disease to Alzheimer’s disease dementia and cognitive function in elderly people: a cross-sectional study. \textit{Lancet Neurol.} \textbf{15}, 934–943 (2016).
11. Patton, N. \textit{et al.} Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvascularatures. \textit{Journal of Anatomy} \textbf{206}, 319–348 (2005).
12. Berisha, F., Feke, G. T., Trompe, C. L., McMeel, J. W. & Schepens, C. L. Retinal abnormalities in early Alzheimer’s disease. \textit{Investig. Ophthalmol. Vis. Sci.} \textbf{48}, 2285–2289 (2007).
13. Corvi, F. \textit{et al.} Impact of intravitreal ranibizumab on vessel functionality in patients with retinal vein occlusion. \textit{Am. J. Ophthalmol.} \textbf{160}, 45–52 (2015).
14. Corvi, F., Querques, G., La Spina, C., Lattanzio, R. & Bandello, F. Dynamic and static retinal vessel analyses in patients with macular edema secondary to retinal vein occlusion. \textit{Retina} \textbf{35}, 2052–9 (2015).
15. Benatti, L. \textit{et al.} Inter-method agreement in retinal blood vessels diameter analysis between Dynamic Vessel Analyzer and optical coherence tomography. \textit{Grasfs Arch. Clin. Exp. Ophthalmol.} \textbf{255}, 1079–1083 (2017).
16. Al-Sheikh, M. \textit{et al.} Quantitative OCT Angiography of the Retinal Microvasculature and the Choriocapillaris in Myopic Eyes. \textit{Invest. Ophthalmol. Vis. Sci.} \textbf{58}, [in press] (2017).
17. Borrelli, E. \textit{et al.} Macular microvascular networks in healthy pediatric subjects. \textit{Retina}, https://doi.org/10.1097/ IAR.0000000000002123 (2018).
18. Sjögren, M. \textit{et al.} Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. \textit{Clin. Chem.} \textbf{47}, 1776–1781 (2001).
19. Tapiola, T. \textit{et al.} Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. \textit{Arch. Neurol.} \textbf{66}, 382–9 (2009).
20. Hansson, O. \textit{et al.} Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. \textit{Lancet Neurol.} \textbf{5}, 228–234 (2006).
21. McKhann, G. M. \textit{et al.} The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. \textit{Alzheimer’s Dement.} \textbf{7}, 263–269 (2011).
22. Albert, M. S. \textit{et al.} The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. \textit{Alzheimer’s Dement.} \textbf{7}, 270–279 (2011).
23. Iafe, N. A., Phasukkijwatanakul, N., Chen, X. & Sarraf, D. Retinal Capillary Density and Foveal Avascular Zone Area Are Age-Dependent: Quantitative Analysis Using Optical Coherence Tomography Angiography. \textit{Investig. Ophthalmol. Vis. Sci.} \textbf{57}, 5780 (2016).
24. La Spina, C., Corvi, F., Bandello, F. & Querques, G. Static characteristics and dynamic functionality of retinal vessels in longer eyes with or without pathologic myopia. \textit{Grasfs Arch. Clin. Exp. Ophthalmol.} \textbf{254}, 827–834 (2016).
25. Benatti, L. \textit{et al.} Dynamic functionality and static changes of retinal vessels in diabetic patients treated with intravitreal ranibizumab. \textit{Acta Diabetol.} \textbf{54}, 39–43 (2017).
26. Lei, J. \textit{et al.} Repeatability and Reproducibility of Superficial Macular Retinal Vessel Density Measurements Using Optical Coherence Tomography Angiography En Face Images. \textit{JAMA Ophthalmol.} \textbf{135}, 1092 (2017).
27. Uji, A. \textit{et al.} Choriocapillaris Imaging Using Multiple En Face Optical Coherence Tomography Angiography Image Averaging. \textit{JAMA Ophthalmol.} https://doi.org/10.1001/jamaophthalmol.2017.3994 (2017).
28. Schneider, C. A., Rasband, W. S. & Elcorier, K. W. NIH Image to ImageJ: 25 years of image analysis. \textit{Nat. Methods} \textbf{9}, 671–5 (2012).
29. Cicinelli, M. V. \textit{et al.} Retinal vascular alterations in reticular pseudodrusen with and without outer retinal atrophy assessed by optical coherence tomography angiography. \textit{Br. J. Ophthalmol.} \textbf{bjophthalmol-2017-311317}, https://doi.org/10.1136/ bjophthalmol-2017-311317 (2018).
30. Cicinelli, M. V. \textit{et al.} Choroid morphometric analysis in non-neovascular age-related macular degeneration by means of optical coherence tomography angiography. \textit{Br. J. Ophthalmol.} \textbf{2016-309481}, https://doi.org/10.1136/ bjophthalmol-2016-309481 (2017).
31. Coscas, G., Lupidi, M. & Coscas, F. Heidelberg Spectralis Optical Coherence Tomography Angiography: Technical Aspects. Dev. Ophthalmol. 56, 1–5 (2016).
32. Kwon, J. Y., Yang, J. H., Han, J. S. & Kim, D. G. Analysis of the Retinal Nerve Fiber Layer Thickness in Alzheimer Disease and Mild Cognitive Impairment. Korean J. Ophthalmol. https://doi.org/10.3341/kjo.2016.018 (2017).
33. Den Haan, J. et al. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. Alzheimer's Dement. Diagnosis Assess. Dis. Monitr., https://doi.org/10.1016/j.jadm.2017.10.005 (2018).
34. Cunha, L. P., Almeida, A. L. M., Costa-Cunha, L. V. F., Costa, C. F. & Monteiro, M. L. R. The role of optical coherence tomography in Alzheimer's disease. Int. J. Retin. Vit. 2, 24 (2016).
35. Marziani, E. et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral-domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 54, 5953–8 (2013).
36. Bulut, M. et al. Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia. Br. J. Ophthalmol. biophthalmol-2017-310476, https://doi.org/10.1136/bjophthalmol-2017-310476 (2017).
37. Hinton, D. R., Sadun, A. A., Blanks, J. C. & Miller, C. A. Optic-Nerve Degeneration in Alzheimer’s Disease. N. Engl. J. Med. 315, 485–487 (1986).
38. Sadun, A. A. & Bassi, C. J. Optic nerve damage in Alzheimer’s disease. Ophthalmology 97, 9–17 (1990).
39. Curcio, C. A. & Drucker, D. N. Retinal ganglion cells in Alzheimer’s disease and aging. Ann. Neurol. 33, 248–57 (1993).
40. Alexandrov, P. N., Pogue, A., Bhattacharjee, S. & Lukiw, W. J. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport 22, 623–627 (2011).
41. Bayhan, H. A., Aslan Bayhan, S., Celikbilek, A., Tanik, N. & Gündal, C. Evaluation of the chorioretinal thickness changes in Alzheimer’s disease using spectral-domain optical coherence tomography. Clin. Experiment. Ophthalmol. 43, 145–51 (2015).
42. Cheung, C. Y. et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J. Alzheimers. Dis. 45, 45–56 (2015).
43. Blanks, J. C., Torigoe, Y., Hinton, D. R. & Blanks, R. H. I. Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parfoveal retina. Neurobiol. Aging 17, 377–384 (1996).
44. Hofman, A. et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet (London, England) 349, 151–154 (1997).
45. White, L. et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann. N. Y. Acad. Sci. 977, 9–23 (2002).
46. Van Exel, E. et al. Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus Study. Atherosclerosis 165, 353–359 (2002).
47. Po, C. et al. Comorbidity in Dementia: An Autopsy Study. Arch. Pathol. Lab. Med. 128, 32–38 (2004).
48. Kokjohn, T. A. & Roher, A. E. Amyloid precursor protein transgenic mouse models and Alzheimer’s disease: understanding the paradigms, limitations, and contributions. Alzheimers. Dement. 5, 340–7 (2009).
49. Patton, N. et al. The association between retinal vascular network geometry and cognitive ability in an elderly population. Invest. Ophthalmol. Vis. Sci. 48, 1995–2000 (2007).
50. Kotliar, K. E., Vilser, W., Nagel, E. & Lanzl, I. M. Retinal vessel reaction in response to chromatic flickering light. Graefe’s Arch. Clin. Exp. Ophthalmol. 242, 377–392 (2004).
51. De La Torre, J. C. & Stefano, G. B. Evidence that Alzheimer’s disease is a microvascular disorder: The role of constitutive nitric oxide. Brain Research Reviews 34, 119–136 (2000).
52. Kalaria, R. N. Small vessel disease and alzheimer's dementia: Pathological considerations. Cerebrovasc. Dis. 13, 48–52 (2002).
53. Kotliar, K. et al. Altered neurovascular coupling as measured by optical imaging: A biomarker for Alzheimer's disease. In Scientific Reports 7 (2017).
54. Wang, X. et al. Optical coherence tomography angiography of optic nerve head and parafovea in multiple sclerosis. Br. J. Ophthalmol. 98, 1368–73 (2014).

Acknowledgements

G. Querques: Allmera Sciences (C), Allergan, Inc. (C), Bayer Schering-Pharma (C), Heidelberg (C), Novartis (C), Sandoz (C), Zeiss (C), E. Borrelli: reports no disclosures; R. Sacconi: reports no disclosures; L. De Vitis: reports no disclosures; L. Leocani: Merck KGaA (C), Biogen Idec (C), R. Santangelo: reports no disclosures; G. Magnani: reports no disclosures; G. Comi: Novartis (C), Teva Pharmaceutical Industries (C), Sanoﬁ (C), Genzyme (C), Merck Serono (C), Bayer (C), and Actelion (C); F. Bandello: Allergan (S), Allmera (S), Bayer (S), Farmi/Thera (S), Schering Pharma (S), Sanoﬁ-Aventis (S), Novagali (S), Pharma (S), Hoffmann-La Roche (S), Genentech (S), Novartis (S).

Author Contributions

G.Q., L.L., G.C. and F.B. conception and design of the study; G.Q., R.S., L.D.V., L.L., R.S. and G.M. patients’ enrolment and data acquisition; G.Q., L.D.V. data analysis; All authors: interpretation of data; G.Q. drafting the article; All authors: revising it critically for important intellectual content.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019